New
CJC-1295 with DAC
79,99 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Sustained increase in GH and IGF-1 with once-weekly administration.
- Increased lean muscle mass and improved body composition.
- Improved fat metabolism, especially visceral fat.
- Improved sleep quality and recovery.
- Supports bone density during long-term use.
Description
CJC-1295 with DAC
Growth Hormone / Anti-Aging
MECHANISM OF ACTION
A GHRH analog using Drug Affinity Complex (DAC) technology, which enables covalent binding to albumin via a lysine-maleimide reaction. It prolongs the half-life to 7–10 days. It continuously activates pituitary GHRH receptors, resulting in a sustained increase in GH and IGF-1. It produces a “drip” of GH rather than a pulsatile release.
KEY BENEFITS
- Sustained increase in GH and IGF-1 with once-weekly administration.
- Increased lean muscle mass and improved body composition.
- Improved fat metabolism, especially visceral fat.
- Improved sleep quality and recovery.
- Supports bone density during long-term use.
SIDE EFFECTS AND SAFETY
Transient water retention, carpal tunnel syndrome-like symptoms at high doses, and potential desensitization with continued use. Monitoring of IGF-1 is recommended. It is not pulsatile, so it may suppress the natural GH rhythm during prolonged use.
RESEARCH AND CLINICAL NOTES
Phase I/II human trials demonstrated 2–10-fold increases in GH AUC for 14 days following injection. IGF-1 rose to 1.5–3 times the baseline level and remained elevated for more than 2 weeks. Walker et al. (2005), JCEM.
TARGET PROFILE:
Anti-aging protocols, HRT treatments, and body optimization programs with weekly injection schedules.
Additional information
| Weight | ,26 kg |
|---|
Related products
New
BPC 5 mg + TB 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Faster soft tissue repair than with any of the peptides alone.
- Coverage for localized repair (BPC-157) and systemic repair (TB-500).
- Reduction of inflammation and pain following an injury.
- Recovery of joints, tendons, ligaments, and muscles.
- A convenient, single-vial protocol for injury recovery.
New
DSIP
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sleep quality, especially deep, slow-wave (delta) sleep.
- Stress-reducing and anxiolytic effects.
- Normalization of disrupted sleep patterns.
- Potential application in opioid/alcohol withdrawal syndrome.
- Geroprotector: Anticancer Properties in Animal Models.
New
GHK-Cu
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
New
KPV
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Powerful anti-inflammatory action in the intestines for IBD, Crohn's disease, and colitis.
- Restoration of intestinal barrier function in intestinal permeability protocols.
- Systemic anti-inflammatory effect without immunosuppression.
- Supports healing and reduces skin inflammation.
- Oral bioavailability for administration targeted at the gastrointestinal tract.
- Safe: extremely low molecular weight and no systemic toxicity.
L-carnitine
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved fat oxidation and energy production.
- Improved exercise performance and reduced fatigue.
- Cardiovascular health: reduces markers of atherosclerosis.
- Improving Insulin Sensitivity in Research on Type 2 Diabetes Mellitus.
- Male Fertility: Sperm Motility and Improved Sperm Count.
- Neuroprotective, with a preference for the acetyl-L-carnitine form for the CNS.
New
Semaglutide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
New
TB500
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Systemic repair and regeneration of soft tissues.
- Accelerated wound healing and scar reduction.
- Improved tissue flexibility and reduced inflammation.
- Cardiac protection and myocardial repair.
- Eye repair in research on corneal regeneration.
- Protection of renal podocytes.
New
Tirzepatide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
Natural Supplements and Vitamins
Nutrition and Fitness
Beauty and Personal Care
Joint and Muscle Health
Digestive Health and Detox
Immune System
Women’s and Men’s Health
Natural Energy and Antioxidants
Cardiovascular Health
Obesity & Metabolism
